The company’s device, CART BP pro, aims to replace bulky arm-constricting monitors that often force patients to endure sleep disruption during the 24-hour monitoring cycles required for drug trials. According to data cited by the company, 70.2% of users report sleep interference with traditional cuffs, leading to a 50% failure rate in data collection for participants with low tolerability. By shifting the measurement point to the finger, Sky Labs claims it can secure more stable long-term vital signs data while reducing the logistical costs associated with trial delays and participant attrition.
Sky Labs Pitches Ring-Based Monitor as Alternative to Traditional Clinical Trials
At the 9th Digital Biomarkers in Clinical Trials Summit in Basel, South Korean firm Sky Labs proposed its cuffless, ring-type blood pressure monitor as a solution to the high dropout rates and data gaps that plague conventional ambulatory blood pressure monitoring in pharmaceutical research.
Sky Labs is already leveraging domestic validation to court global pharmaceutical giants like Roche and Novartis. The device has been integrated into large-scale cohort studies managed by the Korea National Institutes of Health and is formally recognized in the Korean Guidelines for the Management of Hypertension. CEO Jack Byunghwan Lee noted that the company is now seeking strategic collaborations to apply the platform beyond initial drug development, specifically for gathering Real-World Evidence (RWE) on how existing medications interact with daily lifestyle patterns and dosing schedules.
Comments (0)
No comments yet. Be the first!